Global Multiplex Assay Market: Latest Developmental Insights

1
Global Multiplex Assay Market Latest
Developmental Insights Recent years have seen a
paradigm shift in the healthcare and
biotechnology industries due to the introduction
of cutting-edge technologies. Among these
advancements is the emergence of multiplex
assays, which have transformed how researchers
approach diagnostic and research applications. By
consolidating multiple assays into a single
platform, researchers can streamline the analysis
of complex biological samples, resulting in time
and cost savings. According to Inkwood Research,
the global multiplex assays market is expected to
register a CAGR of 8.12 during 2024-2032 and
reach a revenue of 7793.26 million by 2032.

• Multiplex assays have been widely adopted across
  diverse fields, such as clinical diagnostics,
  drug discovery, genomics, and proteomics. This
  blog details the latest developments happening in
  the global multiplex assay market.
• Request a FREE sample of the Multiplex Assay
  Market
• Latest Developments in the Global Multiplex Assay
  Market
• Parhelias Omni-Stainer Enhanced and Automated
  Multiplex Assay
• Understanding cellular function within a given
  microenvironment has become standard practice
  rather than an exception in life sciences
  research. The intricate relationships between
  cells and tissues dictate health outcomes, while
  molecular

2
interactions within and among cells provide
crucial context for understanding their
collective effects.

• Utilizing omics techniques to explore these
  relationships within native tissue environments
  offers spatial insight into cell heterogeneity
  and dynamics. This approach sheds light on
  disease progression, treatment responses, and
  genotype- phenotype correlations at both cellular
  and tissue levels. However, the accuracy of these
  maps depends on the quality of the underlying
  data.
• Implementing automated sample preparation methods
  enhances data consistency, reproducibility, and
  throughput, particularly crucial for multiplex
  assays prone to manual variability and time
  constraints. Parhelia Biosciences envisioned an
  affordable solution to standardize multiplex
  assays, ensuring consistent and reproducible data
  across laboratories of all sizes.
• The Parhelias Omni-Stainer, a fully automated
  system, comprises a robotic chassis, thermal
  module, flow cells, software, and the companys
  S12 staining module accommodating up to 12
  slide-mounted samples. Staining employs capillary
  gap exchange, ensuring uniform coverage, minimal
  reagent waste, and simplified stain removal.
  Additionally, a dedicated thermal module sustains
  precise temperature control (0-99.9C) for
  incubation.
• Affordability was a key consideration in
  developing the Parhelia Omni-Stainer, as similar
  automated systems typically cost between 300,000
  to 500,000, making them inaccessible to many
  laboratories. This drove the team to pursue an
  open- source approach during the development of
  CODEX (now PhenoCycler) at Stanford Universitys
  Nolan Lab.
• Explains Nikolay Samusik, Ph.D., co-founder and
  CEO of Parhelia, Our experience demonstrated
  that accuracy in these assays doesnt require
  paying too much for the fastest, shiniest system,
  which wont automatically translate into solid
  data, Samusik explains. This drove our vision
  to own the spatial biology workflow by providing
  open-source solutions that enable labs of all
  sizes to streamline and standardize assay
  performance to ensure consistency and
  reproducibility. (Source)
• Get CUSTOMIZED market insights delivered right to
  your inbox!
• Enabling Comprehensive Quantification Navigate
  BioPharma Services Incs Cutting-Edge Multiplex
  Digital PCR Assay
• In the 2023 AAPS National Biotechnology
  Conference, Navigate BioPharma Services Inc, a
  subsidiary of Novartis known for its
  groundbreaking biomarker solutions in drug
  development, introduced its latest innovation
  multiplex digital PCR assays. These assays
  provide a comprehensive means of quantifying
  multiple chimeric antigen receptor (CAR) T cells,
  a form of cancer immunotherapy that modifies T
  cells genetically to target and eliminate
  specific cancers. Leveraging
• the Qiagen QIAcuity digital PCR System, these
  assays offer a robust and user- friendly digital
  PCR experience facilitated by its innovative
  nanoplate system.

3
The innovative multiplex digital PCR assay
facilitates simultaneous assessment of the
quantity, activity, and persistence of CAR-T
cells in clinical blood and bone marrow samples,
eliminating the necessity for a standard curve.
It boasts a sensitivity capable of detecting
CAR-T cells as minute as 0.01 within normal T
cell populations, delivering results in under two
hours. Further, this assay accommodates the
measurement of up to five distinct CAR-T cell
markers within a single reaction, utilizing
specific probes tailored to different CAR
targets, thus enabling the quantification of
multiple CAR-domains or combinations of commonly
utilized therapeutic targets in CAR-T therapies.
Such capabilities empower clinicians to monitor
response rates and safety profiles throughout
clinical trials, facilitating the advancement of
novel therapeutic approaches. Says Dr. Nathan
Riccitelli, Associate Director of Innovative
Technologies at Navigate BioPharma Services Inc,
CAR-T therapy is a promising and innovative
approach to treat cancer, but it requires
accurate and reliable quantification of CAR-T
cells for successful drug development. Our new
proprietary multiplex digital PCR assay provides
a comprehensive and robust solution for measuring
CAR-T cells in clinical samples with high
sensitivity, specificity and reproducibility.
(Source) Stay up-to-date with whats trending in
the Global Multiplex Assay Market Future
Potential of Multiplex Assay Market The
development of multiplex tests enables the
simultaneous measurement of multiple analytes in
a single biological sample, minimizing assay
time, cost, and sample volume. For instance, a
multiplex test for respiratory viruses could
deliver sensitive and accurate results right in
the doctors office, facilitating immediate
treatment initiation. Furthermore, multiplex
testing aids laboratories in conserving vital
testing supplies such as pipettes, swabs, and
reagents, all of which are in high demand.
Additionally, it reduces reliance on single-use
tests and enables labs to offer more
comprehensive results in a shorter
timeframe. Moreover, studies have demonstrated
that rapid multiplex testing reduces the length
of stay (LOS) for ICU patients from 9.2 to 6.2
days (P lt 0.0001). In a period marked by boarding
and hospital overcrowding, a shorter LOS during
tripledemics enhances patient flow, thereby
enhancing hospital productivity. Accordingly, the
current and imminent global healthcare landscape
offers lucrative growth opportunities for the
global multiplex assay market. Cant find what
youre looking for? Talk to an expert NOW! 1.
What are multiplex assays? A Multiplex assays
are diagnostic tests that allow the simultaneous
detection and measurement of multiple analytes in
a single sample, streamlining the testing process
and providing comprehensive results.
4

• What are the benefits of using multiplex assays?
• A Using multiplex assays offers several
  advantages, including reduced assay time,
  cost-effectiveness, conservation of testing
  supplies, and the ability to provide
  comprehensive diagnostic information with minimal
  sample volume.
• How are multiplex assays impacting the healthcare
  industry?
• A Multiplex assays are revolutionizing
  diagnostics in the healthcare industry by
  improving efficiency, accuracy, and turnaround
  time for testing. They play a crucial role in
  various applications, including disease
  diagnosis, drug discovery, biomarker analysis,
  and personalized medicine, driving advancements
  in patient care and treatment outcomes.